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Summary 
Epithelial ovarian cancer (EOC) generally presents at an advanced stage and is the most common cause 
of gynecologic cancer death. Treatment requires expert multidisciplinary care. Population based 
screening has been ineffective to date but new approaches for early diagnosis and prevention that 
leverage molecular genomics are in development. Initial therapy includes surgery and adjuvant therapy. 
EOC is composed of distinct histologic subtypes with unique genomic characteristics, which are 
improving the precision and effectiveness of therapy, allowing discovery of predictors of response such 
as BRCA1/2 mutations, homologous recombination (HR) deficiency for DNA damage response pathway 
inhibitors, or resistance (CCNE1). Rapidly evolving techniques to measure genomic changes in tumour 
and blood allow assessment of sensitivity and emergence of resistance to therapy, and may be accurate 
indicators of residual disease. Recurrence unfortunately remains usually incurable, and patient symptom 
control and quality of life are key considerations at that time. Treatments for recurrence have to be 
designed from a patient’s perspective, and incorporate meaningful measures of benefit. Urgent progress 
is needed to develop evidence and consensus-based treatment guidelines for each subgroup, and 
requires close international cooperation in conducting clinical trials through academic research groups 
such as the Gynecologic Cancer Intergroup. 
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Since the last seminar publication 4 years ago1, there have been major improvements in 
understanding invasive epithelial ovarian cancer (EOC) biology (Figure 1), and this has led to changes in 
clinical practice. This manuscript will summarize current optimal evidence-based approach to 
management of EOC.  
 
Epidemiology and Risk Factors 
EOC is the most lethal gynecologic cancer. Annually worldwide, 230,000 women will be 
diagnosed and 150,000 will die2. It represents the seventh most commonly diagnosed cancer among 
women in the world with 46% survival 5 years after diagnosis3. One of the main factors contributing to 
the high death-to-incidence rate is the advanced stage at the time of diagnosis. Late stage presentation 
has 5-year relative survival rate of 29%, in contrast to 92% for early stage disease4. Unfortunately, due to 
its asymptomatic nature, ~75% of patients are diagnosed at an advanced stage. Genomic predisposition 
to EOC is now well recognized in up to 15% of affected women. Breast cancer susceptibility genes 
(BRCA) 1 and BRCA2 have been identified as causative genes involved in 65–75% of hereditary EOC. 
Deleterious mutations in BRCA1/2 and other double-strand DNA break repair genes are largely 
associated with the high grade serous EOC subtype susceptibility. Lynch syndrome, an autosomal 
dominant hereditary cancer family syndrome accounts for 10–15% of hereditary EOC5,6 and is typically 
associated with endometrioid or clear cell tumours4. Additional genetic syndromes include Peutz-Jegher 
and rare disorders7. Risk factors for EOC include the number of lifetime ovulations (absence of 
pregnancy, early age of menarche and late age at menopause), family history of EOC, smoking, benign 
gynecologic conditions including endometriosis, polycystic ovary syndrome and pelvic inflammatory 
disease4, and potentially talc8.  
 
Screening  
Considerable efforts have been made to implement screening of the general population to 
diagnose EOC early, but currently there is no approved strategy9. UKCTOCS, a randomised controlled 
trial of over 200,000 women assessing annual multimodal screening with serum cancer antigen (CA125), 
did not identify significant mortality reduction when the risk-for-ovarian-cancer algorithm was used, 
versus annual transvaginal ultrasound screening, versus no screening. Further follow-up is underway to 
assess late benefit due to a significant stage shift in women diagnosed with invasive ovarian/tubal/ 
peritoneal cancer with multimodal screening compared to no screening10. Additional biomarker 
combinations such as Human epididymis protein 4 (HE4), a glycoprotein secreted by Mullerian epithelia 
of the female reproductive tract, have been tested with CA12511 but further studies are required. A 
study screened 4348 women with ≥10% lifetime risk of ovarian or fallopian tube cancer using the risk of 
ovarian cancer algorithm (ROCA) and transvaginal sonography demonstrating evidence for stage shift 
with 53% of cancers detected during the trial being early stage compared to only 6% of cancers detected 
>1 year after the trial screening finished12. Longer follow-up will determine impact of this strategy on 
survival. The current recommendation for unaffected individuals with a high familial risk of ovarian 
cancer remains risk-reducing salpingo-oophorectomy by an age that depends upon their individual 
genetic predisposition. Efforts are also underway to improve genomic screening strategy13.  
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Diagnosis 
EOC symptoms are not specific and include abdominal bloating, early satiety, nausea, abdominal 
distension, change in bowel function, urinary symptoms, back pain, fatigue and loss of weight, which 
typically present months prior to diagnosis14. Initial investigations include the measurement of CA125 
concentrations and pelvic ultrasound. To accurately define EOC extension, further imaging should 
include chest and abdomen/pelvis CTs for staging, and potentially a pelvic MRI. Optimal staging is 
surgical and includes total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, 
inspection of peritoneal surfaces with biopsy or removal of any suspicious areas, and para-aortic and 
pelvic lymph node dissection. Surgery should be performed by a trained gynaecological oncology 
surgeon with the goal of no residual disease. The staging procedure will establish the surgical stage, 
conventionally using International Federation of Gynecology and Obstetrics staging of ovarian cancer 
(FIGO stage) or AJCC-TNM classifications15,16.  
Pathologic diagnosis on tumor tissue is essential as ovarian cancer has different histology 
subtypes with different treatment approaches. Over the last decade it has become clear that EOC 
consists of a number of diseases (Figure 2) with distinct precursor lesions, tissues of origin, molecular 
biology, clinical presentation, chemosensitivity and patient outcome.  
First Line Treatment Approach 
 
Surgery 
Primary debulking surgery (PDS) followed by chemotherapy has become the standard of care in 
advanced EOC since the eighties, despite the lack of upfront randomized trials defining its actual 
benefit17.  No residual tumour (R0) after PDS is the most important prognostic factor for survival18. Two 
randomized clinical trials comparing PDS and chemotherapy with neoadjuvant chemotherapy (NACT) 
followed by interval debulking surgery (IDS), showed similar survival with a low operative morbidity 
when the latter strategy was used19,20. Both trials have been criticised for their low R0 rates and low 
survival rates. However, it should be noted that the majority of the patients had extensive stage IIIC or 
IV disease. To help the debate, the TRUST trial randomising NACT versus PDS in advanced EOC is on-
going in selected centres with 50% or more R0 rates (NCT02828618). At present the choice between PDS 
and chemotherapy or NACT and IDS remains controversial21.  Further research is needed on how to 
select patients for PDS or NACT, including better and validated imaging or laparoscopic scoring systems 
and algorithms to predict operative morbidity.   
A guideline for selecting patients with FIGO stage IIIC/IV for PDS or NACT followed by IDS is 
presented in Table 122. The algorithm and guideline are based on the EORTC 55971 randomized trial 20 
showing that patients with stage IIIC disease and small metastases (<5 cm) had better overall survival 
(OS) with PDS whereas patients with stage IV disease had better survival with NACT. At the time of 
surgery, it is of outmost importance to remove all visible or palpable tumour at PDS and IDS18,20. For 
decades the role of a full pelvic and para-aortic lymphadenectomy in advanced EOC has been 
advocated23. However, a recent randomized study from AGO-OVAR has shown that systematic pelvic 
and para-aortic lymphadenectomy in patients with advanced EOC with both intra-abdominal complete 
resection and clinically negative lymph nodes does not improve overall or progression-free survival 
(PFS)24.  
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In patients with stage 1A low grade disease opting for fertility conservation surgery, the uterus 
and contralateral ovary can be left in place pending pathology review of the removed tissues and further 
discussion with the patient. The selection of patients for fertility preservation requires very careful 
consideration of the risks and benefits between the surgical oncologist and patient. The likelihood of 
cure is high for women with stage 1A disease, but residual disease and subsequent recurrence are 
associated with low likelihood of salvage. Pathologic differences greatly influence the potential for 
conservative surgery and this option is best reserved for women with well-differentiated or low grade, 
Stage IA disease25. 
 
Systemic Therapy  
The treatment guidelines for EOC have largely been driven by HGSOC and first line therapy has largely 
been established based on this subgroup. 
 
 Early Stage 
Randomized clinical trials in early stage disease have been challenging to conduct as a minority of 
patients present early. ICON and ACTION randomized trials support the use of adjuvant chemotherapy in 
early stage disease, with carboplatin/cisplatin and paclitaxel, with level IA evidence26-31. Subset analyses 
raised the question of a potential to avoid chemotherapy in well-staged early stage patients, but this 
finding should be considered as exploratory32. The question of adjuvant therapy for early stage can be 
discussed based on histology subtype and grade33. The GOG157 trial compared 3 versus 6 cycles of 
adjuvant paclitaxel and carboplatin but was powered to detect a 50% decrease in the recurrence rate at 
5 years34; there was no difference in the arms, perhaps supporting reduction in the number of cycles, 
with reduced toxicity in well-staged patients. However, the standard recommendation in practice 
remains 6 cycles of platinum adjuvant therapy. 
 
 Advanced Stage 
Intravenous (IV) 3-weekly carboplatin (Area under the curve (AUC) 5-6) and paclitaxel (175 mg/m² over 3 
hours) remain the standard chemotherapy drugs for first-line therapy in advanced stage EOC35. Weekly 
IV paclitaxel has recently been investigated and might be an alternative to 3-weekly paclitaxel in 
combination with 3-weekly IV carboplatin. In the JGOG 3016 study, 631 women with stage II-IV EOC 
were randomized between carboplatin AUC 6 with paclitaxel 180 mg/m2 every 3 weeks and carboplatin 
AUC 6 every 3 weeks with weekly paclitaxel 80 mg/m2. A sustained significant improvement in PFS and 
OS for patients receiving dose-dense therapy compared with conventional treatment was reported36. 
However, a benefit in PFS was not seen in three other trials with weekly paclitaxel37-39, possibly due to 
pharmaco-genomic influences since the initial JGOG 3016 trial was in a Japanese population whereas 
the subsequent trials were predominantly in Caucasian populations. 
 Two randomized trials, GOG218 and ICON7 showed a significantly increased PFS, but not OS 
with the addition of the anti-angiogenesis inhibitor bevacizumab (directed against vascular endothelial 
growth factor, VEGF),  to 3 weekly paclitaxel and carboplatin followed by maintenance bevacizumab40,41. 
In a pre-planned analysis of the ICON7 study41, the addition of bevacizumab in women at high risk of 
progression (stage III disease with >1 cm residual disease following PDS, inoperable patients with stage 
III, and stage IV disease), significantly improved estimated median PFS (10.5 months with standard 
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therapy versus 15.9 months with bevacizumab (HR 0.68; 95% CI, 0.55-0.85; p<0.001) and median OS 
(28.8 versus 36.6 months (HR 0.64; 95% CI, 0.48-0.85; p=0.002)). These findings led to the addition of 
bevacizumab to 3-weekly paclitaxel and carboplatin as standard of care in this high-risk population in 
many countries. AGO trials group exploring 15 versus 30 cycles42-44 will confirm or refute the hypothesis 
from ICON7 and ROSIA trials that benefit of bevacizumab is related to the maintenance duration.  
The use of intraperitoneal (IP) cisplatin and paclitaxel has resulted in a survival advantage in 
several trials in patients with <1 cm residual tumour after PDS45-47. These trials have been criticized 
because they were hampered by outdated control arms, experimental IP chemotherapy arms, various 
changes (e.g. different dose, dose dense regimens) and higher toxicity48. The role of IP therapy has 
recently come into question with GOG252 study, assessing IV dose dense versus IP therapy with the 
addition of bevacizumab which did not show any benefit in PFS for patients with FIGO stage III disease 
and <1 cm residual tumour following PDS49. Overall, the picture seems to demonstrate that dose for 
dose, there is no advantage of IP chemotherapy over IV. Studies which were associated with benefit of 
IP chemotherapy used IP cisplatin at 100mg/m2 and were associated with a higher incidence of toxicity. 
Hyperthermic IP chemotherapy (HIPEC) until recently had no proven benefit in EOC50. However, 
in 2017, two randomized studies from Dutch and Korean groups used HIPEC at the time of IDS after 
NACT50-52. The Dutch trial reported significant advantage for the HIPEC group, which was not observed in 
the Korean trial. In the Dutch trial, the median recurrence-free survival and median OS were 10.7 and 
33.9 months in the surgery group versus 14.2 and 45.7 months in the surgery-plus-HIPEC group, 
respectively. In women who received NACT in the Korean trial, the median PFS for HIPEC and control 
group were 20 and 19 months, respectively (log-rank test, p = 0.137) and the median OS for HIPEC and 
control group were 54 and 51 months, respectively (log-rank test, p = 0.407). These trials were small and 
resulted in higher toxicity when HIPEC was used and should be confirmed before HIPEC can be used as 
standard of care53. The key question of whether benefit is related to an additional IP cycle of therapy or 
the potential association with hyperthermia is going to be evaluated in a prospective trial (personal 
communication with Dr. Gupta, Tata Memorial Institute). 
 
Follow-up 
Follow-up may identify disease recurrence earlier, but there are no clear guidelines on the type 
and frequency; regular physical examination is generally recommended. The earliest indication of 
recurrent disease might be CA125 in patients where this has been a marker of disease. With neither 
radiological nor clinical evidence of disease, recurrence can be defined by the rise >2× the upper limit of 
normal (ULN is 35 U/mL) for patients with normal baseline CA125 levels or for those whose CA125 levels 
have normalized during treatment, or CA125 level >2× nadir value (on 2 successive occasions) for 
patients whose CA125 levels have not normalized. The question of value from close monitoring to 
detect recurrence early remains, as no survival benefit was observed with early treatment of relapse 
based on increased CA125 alone54. This might have been due to the lack of effective therapeutic options 
at recurrence, or a limitation of the study, which was underpowered to detect a potential survival 
benefit in patients eligible for secondary cytoreduction. Although early detection may not have survival 
advantage, it does allow for exploration of treatment options, including surgery or experimental 
therapies, which have led to regular follow-up after completion of primary therapy.  
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CT scans can detect an asymptomatic recurrence and should be systematically performed to 
establish a baseline before starting new lines of therapy. Several studies have demonstrated the utility 
of FDG-PET/CT for early detection of recurrent EOC  and MRI in the evaluation of patients with recurrent 
EOC and its potential role of prediction of optimal secondary debulking surgery (SDS)55.  
 
Recurrence 
Unfortunately, recurrence is incurable in ~75% of women who present with advanced disease. A 
functional algorithm utilizing the platinum-free interval (PFI) to select subsequent therapy has been a 
simple and remarkably effective way of choosing therapy and inferring prognosis for last 30 years. 
Recently, the Gynecologic Cancer Inter Group (GCIG) redefined the conventional practice of using PFI to 
categorize patients as platinum-sensitive or resistant, and replaced this by a therapy-free interval (TFI), 
with the remaining cut-off at 6 months56.  
At the time of relapse, SDS should be considered for appropriate patients57. AGO-OVAR 
developed DESKTOP score as a predictive algorithm of effective SDS58. Patients with the first recurrence 
and a PFI of >6 months (platinum sensitive) EOC have a positive DESKTOP score when accompanied by 
good performance status (ECOG 0), complete resection during first line therapy and ascites of less than 
500mL; these patients have a significantly better PFS when undergoing SDS followed by chemotherapy, 
versus chemotherapy alone59. A positive DESKTOP score predicted the probability of complete resection 
in more than 2 out of 3 patients with 95% accuracy58. The Tian Risk model, which is also based on the 
factors impacting on SDS surgical outcome60, utilizes six factors predicting complete cytoreduction: FIGO 
stage (I/II vs. III/IV), residual disease after primary cytoreduction (0 mm vs. >0 mm), PFS (<16 months vs. 
≥16 months), ECOG performance status (0-1 vs. 2-3), CA125 (≤ 105 vs. > 105 U/ml) and ascites at 
recurrence (absent vs. present).  Memorial Sloan Kettering criteria are also used to predict for complete 
gross resection in secondary cytoreductive surgery in EOC61. 
 
If there is no surgical option, systemic therapy is used to control the disease as long as possible. 
Several clinical trials have changed the landscape of care and remain an active area of investigation to 
overcome resistance. The type of treatment will be based on patient, time of recurrence, tumor 
histology and disease biology. Given that high grade serous ovarian cancer (HGSOC) is the most common 
type of EOC, we will focus on this specific group. The other histology subtypes including low grade 
serous, clear cell, endometrioid and mucinous are described in the supplementary (Supplementary).  
 
 High Grade Serous Ovarian Cancer (HGSOC) 
Epidemiology/Origin 
HGSOC is the most common type accounting for 75% of all EOC. The contemporary portrait of 
HGSOC pathogenesis has evolved from the notion that it develops from the ovarian epithelium to the 
epithelium of the distal fallopian tube62. Serous tubal intra epithelial carcinomas (STIC) are suspected to 
be the precursor lesion of some HGSOC, with molecular features involving mutations in TP53 as an early 
event63. Bilateral salpingo oophorectomy is the standard of care for risk-reduction in BRCA1/2 carriers. 
Prevention studies are currently assessing bilateral salpingectomy with delayed oophorectomy in 
women with high risk64.  
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Hereditary susceptibility 
 As 15-20% of HGSOC have germline BRCA1/2 mutations, diagnosis should trigger genetic 
testing65. The confirmation of germline mutation in a patient should also lead to offering germline 
testing offered to the in first degree relatives to identify carriers who may benefit from screening. In 
family predisposition studies, the cumulative risks of EOC by the age of 80 are estimated to be 44% in 
BRCA1 and 17% in BRCA2 mutation carriers66. Female BRCA1/2 carriers should consider prophylactic risk 
reduction surgery after childbearing and around age 38, when the risk of EOC begins to increase as this 
is currently the only proven risk-reducing strategy67. Other genes of moderate penetrance involve 
RAD51C, RAD51D and BRIP1; although their individual mutation frequency is uncommon (<1% each), 
cumulatively they may be responsible for ~5% of EOC. Therefore, a genetic-testing for women with 
HGSOC includes BRCA1/2 and other susceptibility genes68. Current studies are also evaluating early 
detection of TP53 in blood or uterine lavage as a potential genomic screen69,70. 
 
Pathology 
The growth pattern of HGSOC is heterogeneous, involving large papillae, being glandular, solid 
and occasionally micropapillary with frequent necrosis; it is defined by its high grade nuclei and mitotic 
index71 (Figure 2). Immunohistochemistry (IHC) stain is abnormal for p53, diffusely expressed for p16 
and elevated for Ki67; additional markers include ER, PR, WT-1 and PAX8.  
 
Molecular abnormality 
HGSOC is characterised by ubiquitous inactivating mutations in TP5371, high-frequency somatic 
copy number alterations (CNAs), and whole genome duplications72. HGSOC are associated with lower 
prevalence but recurrent somatic mutations in NF1, BRCA1/2, RB1 and CDK1272 in around 5-8% of 
tumours (Figure 3). HGSOC is also characterized with frequent DNA gains and losses, making this cancer 
chromosomally unstable, with potential for acquired chemoresistance (CCNE1 amplification)73. 
Heterozygous and homozygous loss is an important mechanism for inactivation of tumour suppressors74. 
Genomic analyses demonstrate HR is defective in nearly half of HGSOC72. This HR deficiency (HRD) is a 
key determinant of platinum sensitivity in HGSOC and has been exploited for treatment with poly (ADP-
ribose) polymerase inhibitors (PARPi)75. Myriad HRD test and Foundation Medicine loss-of-
heterozygosity (LOH) assay assess HRD in tumours as a potential predictive biomarker for PARPi therapy. 
Molecularly, HGSOC may be stratified into four different prognostic subtypes (C1/mesenchymal, 
C2/immune, C4/differentiated and C5/proliferative)72,76,77 and potentially seven copy-number 
signatures78; both stratification methods require prospective validation to be used in a predictive way. 
 
Treatment  
In the platinum-sensitive recurrence setting, if surgery is not indicated, a re-challenge with 
platinum doublet chemotherapy is standard, with 6-8 cycles of therapy79-82. Maintenance strategies have 
been developed to delay subsequent progression and possibly improve OS83. Phase III trials with 
bevacizumab showed a significant benefit for maintenance on disease control rate84,85. In the OCEANS 
trial, the addition of bevacizumab to carboplatin/gemcitabine increased median PFS from 8.4 and 12.4 
months (HR 0.484; 95% CI, 0.388-0.605; log-rank p<0.0001). GOG213 confirmed the benefit of adding 
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bevacizumab to carboplatin and paclitaxel with improvement in OS after correcting for PFI (HR of 0.823; 
95% CI, 0.680-0.996; p=0.0447)85. 
A re-challenge with chemotherapy plus bevacizumab for platinum-sensitive recurrence and 
patients who previously received bevacizumab as first line showed a clinical benefit with a median PFS 
from 8.8 to 11.8 months without and with bevacizumab, respectively (HR 0.51, 95% CI, 0.41-0.64, 
p<0.001) but no significant difference in OS86. The benefit of adding and continuing an anti-angiogenic 
agent was further confirmed with cediranib87.   
PARPi have been successfully implemented in recurrent HGSOC by leveraging inherent defects in 
DNA repair mechanisms present in around 50% of HGSOC due to mutations in BRCA1/2 or associated 
HRD genes, or functional inactivation through methylation72. PARPi have shown remarkable activity as 
single agent in women with recurrent disease regardless of BRCA1/2 mutation, with improved activity in 
women with BRCA1/2 mutation and platinum-sensitive disease88-91. Olaparib was the first PARPi 
approved initially for the treatment of advanced EOC in patients carrying germline BRCA1/2 mutations 
who have received three or more previous lines of chemotherapy with response rate of 31.1% (95% CI, 
24.6-38.1)89,92. In December 2016, the USA Food & Drug Administration (FDA) granted accelerated 
approval of rucaparib for the treatment of patients with HGSOC carrying deleterious germline or somatic 
BRCA1/2 mutations previously treated with two or more lines of chemotherapy90,93 based on the 
investigator-assessed objective response rate of 54% [95% CI, 44-64], and median duration of response 
of 9.2 months (95% CI, 6.6-11.7). Olaparib was approved in Europe as maintenance treatment in 
patients with platinum-sensitive relapsed HGSOC characterized by BRCA1/2 mutations94. Among 
patients with a BRCA1/2 mutation, median PFS was significantly longer in the olaparib group than in the 
placebo group (11.2 months [95% CI, 8.3-not calculable] vs 4.3 months [3.0-5.4]; HR 0.18 [0.10-0.31]; 
p<0.0001); for patients with wildtype BRCA1/2, the difference was lower (7.4 months [5.5-10.3] vs 5.5 
months [3.7-5.6]; HR 0.54 [0.34-0.85]; p=0.0075)95. In women with BRCA1/2 mutations, SOLO2 trial 
confirmed the significance of maintenance, which was followed by FDA’s approval of olaparib as 
maintenance therapy in women with platinum-sensitive disease following response to chemotherapy96. 
The benefit of maintenance PARPi extends beyond BRCA1/2 mutation and HRD. Following the 
results of the phase III NOVA study, niraparib received FDA approval as maintenance treatment of 
patients with platinum-sensitive recurrent EOC who have achieved a complete or partial response 
following platinum-based chemotherapy regardless of BRCA status97. Patients treated with niraparib had 
a significantly longer median PFS than those treated with placebo, including 21.0 vs. 5.5 months in the 
germline BRCA1/2 cohort (HR 0.27; 95% CI, 0.17-0.41), as compared with 12.9 vs. 3.8 months in the non-
germline BRCA1/2 cohort for patients who had tumours with HRD (HR 0.38; 95% CI, 0.24-0.59) and 9.3 
vs. 3.9 months in the overall non-germline BRCA1/2 cohort (HR 0.45; 95% CI, 0.34-0.61; p<0.001 for all 
three comparisons). The most recent addition to the pharmacopeia has been rucaparib, which 
demonstrated significant benefit for maintenance therapy following a good response to platinum-based 
chemotherapy following recurrence98. Median PFS in patients with a BRCA-mutant carcinoma was 16.6 
months (95% CI, 13.4-22.9) in the rucaparib group versus 5.4 months (3.4-6.7) in the placebo group (HR 
0.23 [95% CI, 0.16-0.34]; p<0·0001); in patients with a HRD carcinoma, it was 13.6 (10.9-16.2) versus 5.4 
months (5.1-5.6; 0.32 [0.24-0.42]; p<0.0001). 
Collectively, the greatest benefit of PARPi as single agent therapy has been observed in women 
with HGSOC containing deleterious germline or somatic mutations in BRCA1/299, followed by women 
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with evidence of HRD; however, biomarkers have not been specific enough to predict benefit. Novel 
strategies are underway to avoid the use of chemotherapy and involve combination of targeting drugs, 
such as olaparib/cediranib100; regardless BRCA1/2 status at the time of platinum-sensitive relapse.  
 
Recurrent disease follows a frequent relapse‐response pattern before becoming resistant to 
treatment. For platinum‐resistant disease, various sequential mono-chemotherapies including weekly 
paclitaxel, liposomal doxorubicin and gemcitabine are used until subsequent progression or 
unacceptable toxicity. However, as the expected response rate in the platinum-resistant setting are low 
(~10-15%), several trials are investigating new agents to overcome resistance101. In the platinum-
resistant setting, a phase III trial (AURELIA) showed that adding bevacizumab to various chemotherapy 
regimens increased the PFS from 3.4 to 6.7 months (HR 0.48 95% CI, 0.38-0.60; unstratified log-rank 
p<0.001). An unplanned exploratory subgroup analysis reported that the PFS benefit was greatest in the 
weekly paclitaxel arm, with an improvement from 3.9 to 10.4 months upon addition of bevacizumab102. 
Patients with refractory disease, defined as progression during the first line of platinum-based 
chemotherapy, have a very poor prognosis with very low response rate to standard chemotherapy. 
Unfortunately, these patients are often excluded from trials and there is an urgent need to define 
options for this group. 
 
Future directions 
After the approval of anti-angiogenics and PARPi, there is an active interest in combination 
therapy to overcome resistance. Acquired drug resistance mechanisms to PARPi involving BRCA 
mutation reversions and ABCB1 fusions are well known but they are often not present in all tumour 
cells103,104, suggesting that multiple resistance mechanisms may be present within an individual patient. 
Research aimed at delineating novel resistance mechanisms is needed. Another area of investigation is 
the immune infiltration and tumour hypoxia105, and how modulating the microenvironment may prompt 
responses to therapy. Since preliminary results of immunotherapy as single agent showed low response 
rates in HGSOC106, novel approaches are based on combination strategy and T-cell therapy107.  
Efforts are also ongoing in improving drug delivery; antibody-drug conjugates (ADCs) are an 
important class of highly potent biopharmaceutical drugs designed as a targeted therapy. ADCs consist 
of an antibody designed against a specific target linked to a cytotoxic agent108. Because targets do not 
have to be drivers of tumour growth, ADCs are an emerging class of therapeutics, particularly in OC 
lacking clear oncogenic drivers. As an example, Mirvetuximab soravtansine (IMGN853) consists of a 
humanized anti-folate receptor (FR) monoclonal antibody attached to the cytotoxic maytansinoid, 
DM4109. This is currently being assessed in phase III trial for patients with FR-positive platinum-resistant 
EOC. The ADC strategy offers the possibility to investigate the interest of functional imaging based on 
the identification of the target and tissue analysis110.  
The current challenge is to define the appropriate combination/sequence strategy for a patient 
at a specific time and then identify mechanisms of resistance that will guide the treatment individualized 
to each patient.  
 
Patient journey: Evolution of disease 
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In HGSOC, TP53 mutation is followed by multiple sequential mutational processes that drive the 
pathogenesis into a highly complex, genomically unstable tumour with low frequency of oncogenic 
mutations and few recurrent copy number alterations111. These aberrations can evolve with time and 
exposure to different lines of treatment, increasing the risk of developing therapeutic resistance. 
Majority of targetable mutations are concordant over time, despite inter-current chemotherapy and 
associated clonal selection112. However, reversion mutations restoring the open reading frame of BRCA 
have been described with PARPi treatment113,114, as well as recovery of BRCA1/2 protein expression115, 
which predict for resistance to therapy116. Whole genome sequencing has elegantly established the 
potency of the somatic genome, characterized with diverse DNA repair deficiencies that can be used to 
stratify ovarian cancers into distinct biological groups with predictive signatures of resistance or 
relapse117. Next-generation sequencing (NGS) is further facilitating deeper understanding of resistance 
and response; in particular, the analysis of exceptional responders in clinical practice allows for 
discovery of predictive signatures that may revitalize or reposition the use of targeted agents118. Unique 
genomic determinants may be associated with the exceptional outcome in HGSOC patients; concurrent 
HR deficiency and RB1 loss were associated with favorable outcomes, suggesting that co-occurrence of 
specific mutations might mediate durable responses119. 
Spatial and temporal intra-tumour heterogeneity is a major challenge for the development of 
precision medicine and treatment120-122. Several new targets have been identified for each tumour type 
and are under evaluation as part of clinical trials (Figures 2-4). Given the complexity involved in the 
mechanisms of therapeutic resistance, the characterization of the disease processes at recurrence is key 
to identify the best treatment strategy for a patient at that time (Figure 5). Combination therapy 
targeting DNA damage response, cell-cycle, signaling pathway and tumour microenvironment may be 
required to control the profound genomic complexity of evolution of OC. This involves a change in 
practice and a need for sequential biopsy, or liquid biopsy, to define the mechanism of resistance 
involved in the current episode of recurrence. Recent studies have shown the feasibility to detect 
reversions mutations in circulating tumour DNA (ctDNA) upon resistance to therapy, suggesting its 
potential clinical utility114,123. Circulating tumour cell collection has demonstrated “real-time” molecular 
characterization of drug-response at multiple time points in some cancers124.  
The cellular, molecular and spatial heterogeneity of ovarian cancer has led to very active 
consideration of harnessing the immune system to target this disease (Figure 6). Tumour infiltrating 
lymphocytes (TILs) are associated with improved clinical outcome in EOC patients125-127; prognostic 
subtypes have also been suggested74,128. Early studies have incorporated interventions with immune 
checkpoint blockade, cancer vaccines, and adoptive cell therapy. Initial trials included all subtypes of 
EOC, and response rates appear to be modest with checkpoint inhibitors as single agent in HGSOC with 
some encouraging activity seen in CCOC129-132. Beyond the PD-1 and CTLA-4 pathways, additional 
tolerogenic mechanisms can be targeted and used in combination with immune therapies, such as 
chemotherapy or anti-angiogenics. The hypothesis that combination with chemotherapy or targeted 
agents will improve immune exposure and activity of EOC has very quickly led to many combinations 
and randomized clinical trials in recurrent and first line setting.  
 
Quality of life – Symptom management 
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Given the potential chronicity of EOC, patients may experience a multitude of relapses and 
treatment-related adverse events (AE) that can impact quality of life (QOL). Efforts are on-going to 
integrate this endpoint into clinical trials and design studies in recurrent disease where the patient 
reported outcomes (PRO) are major endpoints133. At the time of recurrence, the goal of treatment is to 
control the disease and maintain QOL. This means that treatments have to ensure an acceptable safety 
profile and balance symptom benefit with risks, particularly in the platinum-resistant setting134. To 
incorporate a patient’s perspective on side effects, PRO have been integrated into standard reporting of 
AE based on Common Terminology Criteria for Adverse Events (CTCAE) as PRO-CTCAE135,136. 
Malignant bowel obstruction (MBO) is the most common complication of EOC progression and is 
described by patients as the most devastating event experienced over their disease trajectory with a 
median survival of <5 months137. This is a major clinical challenge due to limiting therapeutic options 
associated with substantial symptoms, such as the inability to maintain oral intake, vomiting and 
abdominal pain, which  lead to nutrient deprivation. MBO management is not well defined and includes 
potential surgical or radiology intervention, medical support and the ethical dilemma of total parenteral 
nutrition (TPN). Efforts are on-going to offer a multidisciplinary management including surgery, 
chemotherapy, radiation, interventional radiology and include patients’ preferences138,139. In this setting, 
the question of TPN remains difficult as the selection of patients who will benefit from TPN is not well 
described and the majority of patients will die from cancer process, not starvation140. Early intervention 
of palliative care is also important to improve patient care141,142.  
 
Conclusion 
The efforts on understanding and characterizing the different types of EOC have been leveraged 
into new therapies, transitioning to standard of care. Discovery research is advancing into elegant 
hypothesis driven trials and translational research. 
Access to clinical trials and international collaboration has been crucial in this progress, 
particularly for the rare tumours types. Building strong multidisciplinary network with integration of 
discovery research with clinical practice is key to improve precision medicine that will impact patient 
care. The delivery of value-based and patient-centered care is central to improving outcomes as is 
learning from each patient, from the exceptional responders to the refractory patients. The value of 
cancer treatment is based on clinical benefit, toxicity, and improvements in patient symptoms or QOL in 
the context of cost143. Patient engagement and input should be integrated to make these efforts 
meaningful and measurable. 
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LEGENDS 
Figure 1: Evolving management strategies based on disease biology and molecular profiling of novel 
biospecimens.  Integrated approach combining understanding of ovarian cancer disease biology and 
evolution, application of novel omics-based technologies as a part of research based studies or clinical 
trials. 
Figure 2: Different histological subtypes of epithelial ovarian cancers and their salient features. HGOSC 
stands for High grade ovarian serous cancer; LGOSC stands for Low grade ovarian serous cancer. P53 
and WT1 staining in HGOSC is shown. The magnifications for H & E pictures range between 50-400x, 
whereas, IHC is 50x. 
Figure 3: Common molecular abnormalities in ovarian cancer. The pie chart on the left demonstrates 
the breakdown of epithelial ovarian cancer according to histological subtype. The pie chart on the right 
shows the breakdown of the main molecular abnormalities that are felt to drive high grade serous 
ovarian tumours (P53 mutation is an almost ubiquitous finding). EMSY: EMSY, BRCA2 Interacting 
Transcriptional Repressor 
Figure 4: Different molecular targets and pathways in ovarian cancers currently developed or under 
investigation. The molecular targets may arise from within a cancer cell or from the tumour 
microenvironment, such as host immune cells or vascular tissue. 
Figure 5: Disease evolution and treatment options in ovarian cancer. Combination therapy targeting 
DNA damage response, cell-cycle, signaling pathway and tumour microenvironment may be required to 
control the profound genomic complexity of evolution of HGSOC. Bevacizumab: vascular endothelial 
growth factor (VEGF) inhibitor. Olaparib, niraparib, rucaparib: Poly (ADP-ribose) polymerase (PARP) 
inhibitors. SDS: secondary debulking surgery. M: maintenance. T: therapy. TBD: to be determined. 
Vertical red lines: time of recurrence. 
Figure 6: Different Immunotherapeutic strategies in targeting ovarian cancers. This ranges from 
targeting the ovarian cancer cells, the tumour microenvironment or boosting the host immune system. 
Table 1.  Leuven and Essen criteria for considering neoadjuvant chemotherapy (NACT) and interval 
debulking surgery (IDS) in FIGO stage IIIC and IV ovarian carcinoma. Adapted from Vergote et al144.   
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Low grade serous ovarian cancer (LGSOC) 
Epidemiology 
The most up to date information regarding LGSOC demographics comes from retrospective 
analysis of 350 patients from the MD Anderson LGSOC longitudinal database1. The median age of 
diagnosis was 46 years and 96% of patients presented with disease spread beyond the pelvis. The 
median PFS (28 months) and OS (102 months) were well in excess of what would be expected for HGSOC 
but due to the younger age at diagnosis (median 10-15 years younger than HGSOC), LGSOC still accounts 
for a considerable number of life years lost. Multivariate analysis of this dataset also demonstrated 
superior outcome for patients aged >35 years at diagnosis (HR=0.53, p<0.001) and those with no disease 
evident at the end of primary surgery (HR=0.56, p<0.001)1. 
 
Genetics/molecular biology 
LGSOC is characterised by frequent activation of MAPK pathway, which might associate with 
superior survival2. KRAS is the most frequently mutated gene (19-35%)3-6 followed by BRAF (2-33%)3-6  
and NRAS (22%)3. BRAF mutations might be more frequently associated with serous borderline tumours 
or early stage LGSOC, and under-represented in late stage or relapsed disease5. Additional genetic 
abnormalities in LGSOC include mutations in NF1, EIFIAX, USP9X and FFAR1 genes3,7; TP53 mutations are 
very rare. Interestingly, growing evidence suggests the importance of endocrine therapy in LGSOC; in a 
series of 26 LGSOC, ER (oestrogen receptor) was expressed in 81%, PR (progesterone receptor) in 35%, 
AR (androgen receptor) in 54%, LHR (lutenizing hormone receptor) in 65%, GnRHR (gonadotropin 
hormone releasing hormone) in 100% of cases8.  
 
Non-genetic risk susceptibility 
Serous borderline tumours are identified in association with 60% of LGSOC9 but the actual 
percentage of serous borderline tumours that subsequently relapse as LGSOC needs to be confirmed; 
studies have reported the rate to be as low as 2%10.  
 
Diagnosis 
In 2004, Malpica et al described a two-tier system for grading serous ovarian cancer that is 
based on nuclear atypia and mitotic rate, as opposed to the previously used three-tier FIGO system9. 
These patients had co-existent serous borderline tumours in 60% of cases9. Clarification of the molecular 
biology and discrete clinical behaviour confirms that this dichotomisation successfully distinguishes 
LGSOC and HGSOC as separate clinical entities. In young patients, germ cell tumours are included in the 
differential diagnosis; this includes assessment of serum LDH, AFP, β-HCG as well as inhibin and CA125. 
 
Treatment 
Primary resection to zero macroscopic residual disease is associated with superior PFS and OS1. 
Given the relative chemo-resistance of LGSOC, complete surgical resection is the primary treatment of 
choice; neoadjuvant chemotherapy is not recommended. The radiological response rate to NACT was 
4% and although a further 88% achieved stable disease, the latter figure may reflect innate disease 
biology rather than chemosensitivity11. In young patients, consideration of fertility issues (and pre-
surgical counselling) is important. A recent large retrospective study has suggested that first-line 
maintenance therapy with hormonal agents significantly extends PFS in stage II to IV LGSOC12. Median 
PFS for the observation group was 26.4 months (95% CI, 21.8-31.0), compared with 64.9 months (95% 
CI, 43.5-86.3) for the hormonotherapy group (p<0.001); OS was not significantly different (102.7 vs. 
115.7 months; p=0.42). These data have led to calls for a prospective randomised study to identify the 
optimal first line systemic treatment strategy.  
In the relapsed disease setting, the response rate to chemotherapy was low ~4%13 and hormonal 
treatment can be a reasonable option. SDS appears to be a valid strategy if complete resection can be 
achieved. In a retrospective review of 41 LGSOC cases, patients with no gross macroscopic residual had a 
median PFS of 60 months vs. 11 months for patients with gross residual (p=0.008) and a median OS of 
167 months vs. 89 months (p=0.1)14. In addition, MEK inhibition is also actively explored. A phase II study 
of selumetinib demonstrated a 15% response rate in heavily pre-treated patients15 whereas the results 
from randomised studies on other MEK inhibitor are pending. Although BRAF mutations are fairly rare in 
relapsed or persistent LGSOC, there are case reports of impressive efficacy of BRAF inhibitors in specific 
cases of V600E mutations16,17. A retrospective single institution study of 40 patients who received 
bevacizumab (mostly in combination with chemotherapy) reported a 47% response rate with a further 
30% disease stabilisation rate18. Given the low response to chemotherapy in LGSOC, it is likely that much 
of this efficacy is contributed to bevacizumab.  
 
Focus areas for future research 
The optimal first line treatment still remains to be defined. Hormone therapy may be important, 
but a randomised first line study is required to answer this question. The role of MEK inhibition remains 
to be defined, as does the role of biomarkers for selecting patients for MEK inhibition. The molecular 
features of LGSOC cases without MAPK activation also remain to be described. 
Clear cell ovarian cancer (CCOC) 
 
Epidemiology 
The median age of diagnosis of CCOC is 55 years19. CCOC makes up 5-12% of all EOC in North 
American populations19,20 but 24% and 19% in the Japanese and Taiwanese cohorts, respectively21,22.  In 
Japan, Taiwan and Korea there is a steady rise in incidence of CCOC that has not yet peaked19,22,23. The 
reason for the geographical or racial difference in incidence is not clear but Japanese-Americans with 
CCOC comprise 9% of EOC diagnoses in USA, compared to 3% in whites and Hispanics24, suggesting that 
both environmental and genetic factors impact on CCOC incidence. In the context of the disease stage, 
in North American populations CCOC makes up 26% of all early (stage I/II) disease compared to 5% of all 
advanced (stage III/IV) disease20, in contrast to HGSOC that makes up 36% of all early stage and 88% of 
all advanced stage disease20. 
Early stage CCOC has a better prognosis than early stage serous ovarian cancer25,26; however, in 
the advanced stage setting, the prognosis of CCOC is worse26,27 likely due to its high level of inherent 
chemotherapy resistance. Patients with relapsed CCOC have a significantly inferior post-relapse survival 
compared to patients with relapsed serous ovarian cancer (HR =2.35; p<0.0001)28. 
 Genetics/molecular biology 
The only common familial syndrome associated with the development of clear cell ovarian 
cancer is Lynch syndrome; a systematic review suggested that ovarian cancer patients with Lynch 
syndrome had a predominance of endometrioid and clear cell histology29. This was confirmed in a recent 
exome-sequencing study in which cases of hypermutated CCOC genomes were associated with germline 
or somatic MMR gene mutations30. 20% of patients with clear cell or endometrioid ovarian cancer have 
loss of mismatch repair (MMR) protein expression31. Approximately two thirds of these loss events are 
due to germline mutation in one of the four main MMR genes (MLH1, MSH2, MSH6 or PMS2). On the 
basis that cancers with MMR gene deficiency have a high chance of responding to immune checkpoint 
inhibition this is currently being tested in prospective clinical trials in these histological subtype32. 
The molecular basis for the link between endometriosis and both clear cell and EOC was made in 
a pivotal study which sequenced whole transcriptomes from 18 CCOCs and found somatic mutations in 
the ARID1A gene in six of the samples33; this was later validated in a much larger tissue set. They also 
identified ARID1A mutations and loss of BAF250a (the protein product of ARID1A) in tumour and 
adjacent areas of endometriosis but not in distant endometriotic lesions, providing evidence of cause 
and effect. ARID1B and SMARCA4, involved in the chromatin remodelling process, have also been 
implicated in CCOC. Other molecular abnormalities associated with CCOC are mutational activation of 
the PI3K/AKT and MAPK pathways (Figure 3)30,34; interestingly, patients with activating mutations of 
either the PI3K/AKT or MAPK pathway might have better prognosis than patients without these 
mutations34. 
 
Non-genetic risk susceptibility 
In a very large study comprising 13,226 controls and 7,911 women with invasive ovarian cancer, 
self-reported endometriosis was associated with a significantly increased risk of clear cell (odds ratio, 
OR, 3.0, p<0.0001), low grade serous (OR 2.1, p<0.0001) and endometrioid (OR 2.0, p<0.0001) ovarian 
cancer35. No association with HGSOC or mucinous ovarian cancer was identified. In a small retrospective 
study comparing CCOC arising in endometriosis to CCOC not arising in endometriosis, the endometriosis-
associated patients were younger, have unilateral tumours and less likely to have ascites36. 
 
Diagnosis 
CCOC usually presents with an isolated pelvic mass (bilaterality occurring in around 2%)37 and 
55% of CCOC present with stage 1 disease27. Cross-sectional imaging with CT or MRI scan is a pre-
operative requisite; CCOC is the most likely histotype to have a poor uptake of fluorodeoxyglucose in 
positron emission tomography38. Expert pathological diagnosis is crucial since HGSOC with clear cell 
change can often be mistaken for bona fide CCOC39. 
 
Treatment 
Given the relative chemo-resistance of CCOC, complete surgical resection is the primary 
treatment of choice; neoadjuvant chemotherapy is not recommended. Data from the MITO-9 study 
suggested that lymphadenectomy improved disease-free and OS in Italian CCOC patients40. This benefit 
may be due to stage shift, although clearly the inclusion of lymphadenectomy is beneficial in terms of 
providing the most accurate staging information. Many guidelines recommend use of adjuvant 
chemotherapy for all stages of CCOC but retrospective subgroup analyses of the pivotal ACTION study of 
chemotherapy in early stage ovarian cancer as well as subsequent retrospective cohort analyses casted 
doubt on the impact of chemotherapy in CCOC since early stage CCOC patients had no significant 
disease free survival benefit from use of adjuvant chemotherapy (63 patients; p=0.4). In contrast, early 
stage serous ovarian cancer patients did derive disease free survival benefit from adjuvant 
chemotherapy (156 patients; p=0.01)37. In a retrospective analysis of 1,995 stage I CCOC patients from 
the Surveillance, Epidemiology, and End Results (SEER) database, no benefit for adjuvant chemotherapy 
was identified at any substage of disease, although this result could have been affected by selection bias 
as chemotherapy was more likely to have been used in patients with higher disease sub-stage41. 
In the setting of advanced (stage III/IV) CCOC, a retrospective analysis performed by the Hellenic 
Cooperative Oncology Group showed a response rate of 45% to first-line platinum-based chemotherapy 
compared to an 81% response rate in serous ovarian cancer42. This is likely an overestimate of CCOC 
chemosensitivity because some of these tumours may be HGSOC disguised as CCOC39,43. In a later 
retrospective study that had the advantage of formal central pathology review, the response rate to 
chemotherapy was 32% compared to 78% in serous ovarian cancers27. In an attempt to improve the 
efficacy of first line chemotherapy in CCOC, an international randomised phase III trial of irinotecan plus 
cisplatin versus carboplatin and paclitaxel was performed in 667 patients with stage I-IV disease but no 
significant benefit was demonstrated in the test arm44. In 72 patients with relapsed CCOC from the 
MITO-9 study, the response rate to platinum-based chemotherapy was a surprising 80% in patients with 
a PFI >6 months45. The response rate to non-platinum chemotherapy in platinum-resistant patients was 
33%, although a high response rate (8/12 patients; 66%) was seen with gemcitabine45. 
Given the molecular similarities between CCOC and clear cell renal carcinoma, sunitinib has 
been used in advanced CCOC with some efficacy46,47; results from the recent GOG254 study are pending. 
While ovarian cancer immunotherapy has largely failed to deliver the results seen in other cancers, 
success has been observed in CCOC patients48,49, potentially due to MMR deficiency that is known to 
confer high mutational load and sensitivity to immune checkpoint blockade32. Radiotherapy had no 
benefit for patients with stage IA, IB or IC (rupture alone) patients, but in other stage IC and stage II 
patients, it improved 5-year disease-free survival by 20%50. 
 
Focus areas for future research 
Considerable uncertainty still exists regarding the extent of benefit and optimal chemotherapy 
in the first line early stage, first line late stage and relapsed disease settings. It may be that immune 
checkpoint inhibitors and small molecules targeting specific intracellular pathways will be more 
successful. Clarifying these matters will require international clinical trials with very rigorous pathology 
review and confirmation by molecular profiling in order to ensure that only bona fide CCOC are 
included. 
 
Endometrioid Ovarian Cancer 
 
Epidemiology 
Endometrioid ovarian cancer is the second most common type of EOC. Synchronous diagnosis of 
endometrioid cancers in the uterus at same time as diagnosis of ovarian cancer is well described51 and 
may occur in about 5% of newly diagnosed EOC52. Whole genome sequencing has identified a common 
ancestry of synchronous ovarian and endometrial cancer and late development of peritoneal carcinoma 
from the same ancestry clone after a period with established endometriosis53. Epidemiologic studies 
suggest that endometrioid and clear cell ovarian cancers arise from the endometrium54 with 
demonstrated differences in cell linage: endometrioid carcinomas seem to arise from the cells of the 
secretory cell lineage, whereas clear cell carcinomas arise from the ciliated cell lineage55. 
 
Molecular Biology   
High grade endometrioid OC (HGEOC) shares some clinical and biological features of HGSOC 
with TP53 gene abnormalities. Low grade endometrioid OC (LGEOC) showed mutations in PI3KCA, BRAF, 
and KRAS are prevalent. 
 
Treatment 
At initial diagnosis, there has been a consideration for performing surgery as the only 
intervention in women with well-differentiated or moderately-differentiated stage IA or IB disease. 
Surgery has to include full staging with hysterectomy, bilateral salpingo-oophorectomy, and 
omentectomy with assessment of undersurface of the diaphragm. Additionally, collection of biopsies of 
the pelvic and abdominal peritoneum and the pelvic and para-aortic lymph nodes, as well as peritoneal 
washings, should be performed56-58.  For HGEOC, the treatment choices are similar to HGSOC, as these 
are both high-grade cancers, characterized by initial chemosensitivity with subsequent acquisition of 
increasing resistance at each recurrence. LGEOC shows more indolent behavior and retrospective 
studies describe low response rates to cytotoxic and hormonal agents. 
Mucinous ovarian cancer 
Mucinous ovarian cancers are most commonly diagnosed at an early stage. Differentiation 
between primary and metastatic involvement of the ovary is critical for optimal patient management59. 
The incidence of true advanced ovarian mucinous tumours has reduced due to the systematic use of 
systemic IHC for the cytokeratins CK7 and CK20, which help to distinguish ovarian from the more 
common gastrointestinal source of these cancers. The percentage of ovarian carcinomas represented by 
primary mucinous tumours is ~ 2.4%60. This rare type of cancer has nearly 100% KRAS mutation and a 
high frequency of HER2 amplification1. Given that this tumour is often chemoresistant, upfront surgery 
is the cornerstone of the treatment; the value of adjuvant chemotherapy is unclear. The poor response 
to chemotherapy is most notably seen in advanced or recurrent disease where there is a need to 
develop systemic treatments61. 
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Fast Facts 
Ovarian cancer – Lancet Oncology 
 Ovarian cancer consists of a number of diseases: high grade serous, low grade serous, clear cell, 
mucinous and endometrioid ovarian cancer; each subtype is associated with distinct precursor 
lesions, tissues of origin, molecular biology, clinical presentation, chemosensitivity and patient 
outcome. As such, treatment decisions are no longer based on staging of the disease, but on 
histology type and an array of its features that are most likely to contribute to drug response in 
the absence of definitive predictive markers. 
 Majority of ovarian cancers develop sporadically, but approximately 10-15% are hereditary. 
Within the hereditary group, 65-75% of cases are caused by inactivating BRCA1/2 gene 
mutations, whereas 10-15% of cases have been found to be are associated Lynch syndrome. 
 Diagnosis is hampered by non-specific symptoms and as such, majority of patients are 
diagnosed with late presentation of the disease. Disease staging is surgical and additional 
investigations include the measurement of CA125 concentrations and imaging. 
 As clinical studies were predominantly conducted on the common subtype (high grade serous), 
evidence base established by landmark studies for treatment of ovarian cancer mainly relate to 
this particular subtype. Clinical trials need to be conducted on subtypes that are rare, such as 
clear cell, low grade serous, mucinous and endometrioid ovarian caner, in order to establish a 
subtype-specific standard of care. 
 First line therapy includes primary debulking surgery with the goal of no residual disease, 
followed by 6 cycles of platinum based chemotherapy. High-grade serous and endometrioid 
ovarian cancer are initially chemosensitive, compared to relative chemoresistance of low grade 
serous, clear cell and mucinous ovarian cancers.  
 Improvements have been demonstrated with targeted agents. In advanced stage with residual 
disease after primary debulking surgery, the addition of anti-angiogenic agent bevacizumab to 
the first line chemotherapy has shown improvement in progression-free survival and overall 
survival.   
 Recurrence is seen in 75% of women who present with advanced disease. This is often an 
incurable situation but with improved understanding of the biology, maintenance strategies 
have been developed to delay subsequent progression and possibly improve overall survival. In 
this setting, bevacizumab and PARP (poly (ADP-ribose) polymerase) inhibitors (olaparib, 
niraparib, rucaparib) have been remarkably effective in controlling the disease.  
 The road to understanding the mechanisms of drug resistance is still a long one and it will 
involve a multi-dimensional approach investigating genomic, transcriptomic, proteomic, 
epigenetic and microenvironmental changes during ovarian cancer trajectory, as well as 
designing better clinical trials, to overcome drug resistance and improve outcomes. 
 Clinical challenges remain during the end-of-life stage when patients develop malignant bowel 
obstruction and other complex issues that do not have well defined management approach. 
Early intervention of palliative care is also important to improve patient care and quality of life. 
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• Highly aggressive tumors
• Papillary or solid growth pattern 
• Tumor cells with atypical, large  irregular nuclei
• High proliferative rate
• Initial chemo-sensitivity with subsequent acquisition of increasing 
resistance
• Key targets: TP53, BRCA1/2, HRR genes
HGOSC
LGOSC
Mucinous
Clear Cell
Endometrioid
• Indolent behavior
• Micro-papillary pattern
• Tumor cells with small uniform nuclei
• Low proliferative rate
• Relative chemo-resistance 
• Key targets: BRAF, KRAS, NRAS and PIK3CA 
• Large size tumors filled with mucus like material
• Early stage diagnosis
• Chemo-resistant
• Key targets : KRAS, PIK3CA and HER2 amplification
• Glycogen containing cells with clear cytoplasm
• Tubulo-cystic, papillary, solid or mixed patterns
• Frequently associated with endometriosis
• Early stage diagnosis
• Poor prognosis and resistance to chemotherapy
• Key targets: PIK3CA, ARID1A and PTEN
• Solid and cystic patterns
• Frequently associated with endometriosis
• Low grade share the same profile as LGSOC
• High grade share similarity with HGSOC
• Key targets : PIK3CA, PTEN, ARID1A, POLE, MMR deficiency
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• Challenging the tumor mutation burden
• Targeting mutation neo-antigens
• Probing the biomarkers at DNA/RNA level that 
predict treatment response
• Adoptive cell therapy
• Immune-checkpoint blockades
• Anti-angiogenics
• Active tumor microenvironment
• Presence of tumor infiltrating cells
• Suppression of IDO expression
• Priming the immune cells with chemo- and radiotherapy
• Using cancer vaccines to generate potent effector T-cells
• Use of synthetic TCR or CAR modified T cells
• Replenishing the gut microbiome
Criteria Essen criteria Leuven criteria
diagnosis: Biopsy with histologically proven epithelial ovarian (or tubal or peritoneal) cancer FIGO stage IIIC-IV
- or fine needle aspiration proving the presence of carcinoma cells in patients with a 
suspicious pelvic mass if CA125 (KU/L)/CEA (ng/mL) ratio is > 25. If the serum CA125/CEA 
ratio is ≤ 25, imaging or endoscopy is obligatory to exclude a primary gastric, colon or 
breast carcinoma
abdominal metastases: involvement of the superior mesenteric artery
diffuse deep infiltration of the root of the small bowel
diffuse and confluent carcinomatosis of the stomach and/or small bowel involving such large parts that resection would lead to a short bowel syndrome or a total gastrectomy
multiple parenchymatous liver metastases in both lobes intrahepatic metastases
tumor involving large parts of the pancreas (not only tail) and/or  the duodenum infiltration of the duodenum and/or pancreas and/or the large vessels of the ligamentum
hepatoduodenale,  truncus coeliacus or behind the porta hepatis
tumor infiltrating the vessels of the lig. hepatoduodenale or truncus coeliacus
extra-abdominal metastases: not completely resectable metastases, as eg.
- multiple parenchymal lung metastases (preferably histologically proven)
- non resectable  lymph node metastases 
- brain metastases
all  excluding: 
- resectable inguinal lymph nodes 
- solitary resectable retrocrual or paracardial nodes
- pleural fluid containing cytologically malignant cells without proof of the 
presence of pleural tumors
patients characteristics / others impaired performance status and co-morbidity not allowing a “maximal surgical effort” to achieve a complete resection
patients’ non-acceptance of potential supportive measures as blood transfusions or temporary stoma 
Criteria for interval debulking: - upfront surgical effort in an institution without expert surgical skills / 
infrastructure
- barrier for initial surgery has disappeared (eg. improved medical condition)
- not, if reason for primary chemotherapy was tumor growth pattern diagnosed 
during open surgery by an experienced gynecologic oncologist under optimal 
circumstances (as in GOG study 152)
- No progressive disease, and
- In case of extraabdominal disease at diagnosis the extraabdominal disease 
should be in complete response or resectable, and
- Performance status and co-morbidity allowing a maximal surgical effort to no 
residual diseases.
Table 1. Leuven and Essen criteria for considering neoadjuvant chemotherapy (NACT) and 
interval debulking surgery (IDS)  in FIGO stage IIIC and IV ovarian carcinoma (Adapted from 
Vergote I., du Bois A., Amant F., Heitz F., Leunen K., Harter P. Neoadjuvant chemotherapy in 
advanced ovarian cancer: On what do we agree and disagree? Gynecol Oncol. 2013;128(1):6-
11) 
